Dr. John Mottershead has reviewed 11 presentations he found particularly interesting.
Those topics are:
– Revised McDonald criteria 2023
– Does high-dose simvastatin slow progression of disability in SPMS?
– Efficacy of tolebrutinib in non-relapsing SPMS: the HERCULES trial
– New clinical subtypes of MS identified
– Unveiling specialists’ views on MS prognostication
– Misdiagnosis of MS in an adult neurogenetics clinic
– Safety and efficacy of frexalimab in RMS
– Short-term B cell depletion results in long-term freedom from disease activity in some RMS patients
– Impact of alternate-day fingolimod tapering on rebound disease activity in MS
– B cell tailored dosing vs standard interval dosing of ocrelizumab
– High efficacy treatment discontinuation vs continuation in patients older than 50 with stable MS
Click here to download PDF of the ECTRIMS_2024_Conference_Review